Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02420912Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationTreatment